| Effects of apolipoprotein and low density lipoprotein receptor gene polymorphisms on lipid metabolism, and the lipid risk factors of coronary artery disease | ||
|---|---|---|
| Prev | Chapter 5. Results | Next |
To evaluate the effect of Lp(a) on the severity of CAD, the population was divided into two groups according to the Lp(a) value (Lp(a) ≥ 35 mg/dl and Lp(a) < 35 mg/dl). Twelve percent of the controls, 17% of the patients with < 50% stenosis and 29% of the patients with > 50% stenosis had high (≥ 35 mg/dl) Lp(a) (c2 = 5.482 and p = 0.019).
High Lp(a) concentrations were most frequent among the patients with the apo E 3/4 or 4/4 phenotype, whilst none of the controls with the apo E 2/3 or 2/4 phenotype had an Lp(a) concentration higher than 35 mg/dl (Table 5-7).
Table 5-7. Apolipoprotein E phenotypes in controls and patients with high lipoprotein(a)
| ControlsLp(a) ≥ 35mg/dl (%) | PatientsLp(a) ≥ 35mg/dl (%) | |
|---|---|---|
| Males* | ||
| E 3/4 or 4/4 | 13 | 38 |
| E 3/3 | 19 | 25 |
| E 2/3 or 2/4 | 0 | 33 |
| Females** | ||
| E 3/4 or 4/4 | 10 | 29 |
| E 3/3 | 6 | 10 |
| E 2/3 or 2/4 | 0 | – |
| * Cochran-Mantel-Haenszel statistics value=11.6 p=0.001, ** Cochran-Mantel-Haenszel statistics value=2.4 p=0.11. | ||
The effect of RS-86505-007 on the Lp(a) concentration was studied in patients receiving the higher 6 mg dose. The median Lp(a) concentration was 11.9 mg/dl (range 1.4-44) after the diet phase and 13.1 mg/dl (range 1.4-49) after drug treatment, but the difference was not statistically significant.